NICE recommends Erbitux for colorectal cancer indication
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment agency for the national health service in England and Wales, has confirmed its recommendation of Merck Serono's (Merck KGaA) Erbitux (cetuximab) as a first-line treatment for metastatic colorectal cancer.